6/30/23, 12:38 AM Val-HeFT Pathway Feedback Search Clinical Topics Home Studies Val-HeFT Val-HeFT Disease Heart failure Trial question What is the role of valsartan in patients with HF of NYHA class II, III, or IV on a stable background of standard therapy? Study design Multi-center Double blinded RCT Population Characteristics of study participants 20.0% female N = 5010 80.0% male 5010 patients (1005 female, 4005 male) Inclusion criteria: patients with HF of NYHA class II, III, or IV on a stable background of standard therapy Key exclusion criteria: pregnancy; postpartum cardiomyopathy; right HF caused by pulmonary disease; rapidly deteriorating HF; hypertrophic cardiomyopathy; clinically important renal, hepatic, or hematological disorders Interventions N=2511 valsartan (160 mg BID) N=2499 placebo (matching placebo BID) Primary outcome Death, cardiac arrest, hospitalization for heart failure, or receipt of intravenous inotropic or vasodilator therapy for heart failure https://web.pathway.md/studies/rec71Z5dZTO75jgKt 1/2 6/30/23, 12:38 AM Val-HeFT Pathway 32.1 % 32.1 28.8 24.1 % 16.1 % Significant decrease 8.0 % NNT = 30 0.0 % Valsartan Placebo Significant decrease in death, cardiac arrest, hospitalization for HF, or receipt of intravenous inotropic or vasodilator therapy for HF (28.8% vs. 32.1%; RR 0.87, 97.5% CI 0.77 to 0.97) Secondary outcomes Significant decrease in hospitalizations for HF (13.8% vs. 18.2%; RR 0.76, 95% CI 0.31 to 1.21) Safety outcomes Significant differences in adverse events leading to discontinuation of drug (9.9% vs. 7.2%, p < 0.001). Conclusion In patients with HF of NYHA class II, III, or IV on a stable background of standard therapy, valsartan was superior to placebo with respect to death, cardiac arrest, hospitalization for HF, or receipt of intravenous inotropic or vasodilator therapy for HF. Reference Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 Dec 6;345(23):1667-75. Open reference URL https://web.pathway.md/studies/rec71Z5dZTO75jgKt 2/2